Vokinger Kerstin - Institute of Law and Laboratory for Technology, Markets, and Regulation, University of Zurich

基本信息

浏览量：16

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 90 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Shortages of Essential Cancer Medicines: Who is Responsible and What Are the Possible Solutions

Kristina Jenei,Mark P. Lythgoe,Kerstin Vokinger

LANCET ONCOLOGYno. 1 (2024): 23-26

引用0浏览0引用

Time from Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011-2022)

Camille E G Glaus,Miquel Serra-Burriel,Stacie B Dusetzina,Kerstin N Vokinger

Annals of internal medicineno. 10 (2024): 1442-1444

引用0浏览0WOS引用

WHO Shapes Priorities for Medicines? an Analysis of the Applicants and Decision Makers Within the Historical Evolution of the WHO Model Lists of Essential Medicines

Kristina Jenei, Camille E G Glaus,Kerstin N Vokinger

Lancet (London, England)no. 10460 (2024): 1365-1374

引用0浏览0WOS引用

1547P Time from Approval to Reimbursement of New Cancer and Non-Cancer Drugs: A Comparative Analysis Between the US, England, Germany, and Switzerland (2011-2022)

C. Glaus,M. Serra-Burriel, S. Dusetzina,K.N. Vokinger

Annals of Oncology (2024)

引用0浏览0引用

1543MO Analysis of Concordance Between Trial and Target Populations for Cancer Drugs in the US, EU, and Switzerland (2014-2023)

K.N. Vokinger,C. Glaus,M. Serra-Burriel,A. Kesselheim

Annals of Oncology (2024)

引用0浏览0引用

Comparative Analysis of Drug Shortages in the US and Germany (2016 - 2023)

Emanuel Nussli, Miquel Serra-Burriel,Kerstin N Vokinger

The Journal of law, medicine & ethics a journal of the American Society of Law, Medicine & Ethicsno. 2 (2024): 488-497

引用0浏览0WOS引用

Drug Prices after Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses

Miquel Serra-Burriel,Nicolau Martin-Bassols,Gellert Perenyi,Kerstin N. Vokinger

JAMA HEALTH FORUMno. 8 (2024)

引用0浏览0WOS引用

Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany

Kerstin N Vokinger, Emanuel Nussli,Stacie B Dusetzina

JAMA internal medicineno. 9 (2024): 1002-1004

引用0浏览0WOS引用

1701P Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland

M. Serra-Burriel,G. Perényi,Y. Laube,A. Mitchell,K.N. Vokinger

Annals of Oncology (2023): S929-S929

引用0浏览0引用

The cancer premium – explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional studyResearch in context

Miquel Serra-Burriel,Gellért Perényi,Yannic Laube,Aaron P. Mitchell,Kerstin N. Vokinger

EClinicalMedicine (2023): 102087

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn